Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : planning to hold online-only stockholders' meeting on April 28, 2020

share with twitter share with LinkedIn share with facebook
share via e-mail
03/30/2020 | 05:05am EDT

Leverkusen -- Bayer AG plans to hold its Annual Stockholders' Meeting as an online-only event for the first time in its history as a result of the continuing spread of the coronavirus (SARS-CoV-2). The decision taken by the Board of Management makes use of new legislation. Subject to Supervisory Board approval, the virtual Annual Stockholders' Meeting is set to take place on April 28 from 10 a.m. as originally planned. "We welcome the legislator's decision to open the door to online stockholders' meetings in this exceptional situation," said Werner Baumann, Chairman of the Board of Management, "as providing reliability for our stockholders is very important to us, especially during the crisis."

The health and wellbeing of participants in the stockholders' meeting is a top priority for Bayer. That is why in view of the coronavirus pandemic, the Annual Stockholders' Meeting cannot be held in Bonn on April 28 as a physical event that is attended in person, as had originally been planned. Postponing the Annual Stockholders' Meeting would have left stockholders having to wait months to exercise their right to submit questions and cast votes. "That's why we waited to see how the legislator would respond before deciding how to proceed with this year's Annual Stockholders' Meeting," Baumann explained. "Being able to pay out the proposed dividend of 2.80 euros per share entitled to the dividend on time and in full with stockholder approval is very important to us. In doing so, we aim to provide planning security for stockholders and, as previously announced, enable them to appropriately share in our success in 2019 despite the gravity of the current crisis."

A new version of the Notice of the Annual Stockholders' Meeting will be published by April 6, and thus within the time frame set out by the new legislation. The entire Annual Stockholders' Meeting is set to be broadcast on the company's website. Stockholders will have until April 25 to submit questions on the agenda. As in the past, stockholders will be able to exercise their voting rights by submitting a postal vote ahead of the event or by assigning proxies designated by the company, provided they register for the Annual Stockholders' Meeting before the deadline. Stockholders can make use of either option online, including during the event. Further details will be provided in the notice.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

For more information go to www.bayer.com/en/annual-stockholders-meeting-2020

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
05/29BAYER AG : Gets a Buy rating from Bernstein
MD
05/29BAYER : Efficacy of Vitrakvi™ (larotrectinib) further established with con..
PU
05/29BAYER : Elanco proposes divestments of some animal health products in Bayer acqu..
AQ
05/28TCR-2 Therapeutics Hires Key Business Development and Regulatory Affairs Cell..
AQ
05/28FCA Gives Guidance For Common PM(NOC) Trials Involving Multiple Actions
AQ
05/27German chemicals industry sees coronavirus hitting 2020 revenue
RE
05/27Rising Swiss rivalry as Roche and Novartis target same diseases
RE
05/26GLOBAL MARKETS LIVE: Labs step up efforts to find coronavirus vaccine
05/26BAYER AG : Deutsche Bank reaffirms its Buy rating
MD
05/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials
Sales 2020 44 246 M 49 144 M 49 144 M
Net income 2020 4 544 M 5 047 M 5 047 M
Net Debt 2020 29 621 M 32 899 M 32 899 M
P/E ratio 2020 13,9x
Yield 2020 4,81%
Capitalization 59 653 M 66 318 M 66 256 M
EV / Sales 2019
EV / Sales 2020 2,02x
Nbr of Employees 102 201
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,44 €
Last Close Price 60,72 €
Spread / Highest target 81,2%
Spread / Average Target 32,5%
Spread / Lowest Target -55,6%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Paul Achleitner Member-Supervisory Board
Reiner Hoffmann Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-16.60%66 318
JOHNSON & JOHNSON1.97%391 896
ROCHE HOLDING AG5.96%295 228
PFIZER, INC.-2.53%212 139
MERCK & CO., INC.-11.25%203 745
NOVARTIS AG-9.65%190 274